PGNewsroom



Value has improved for our Noonan Spectrum Disorders/Rasopathies Panel

Published on

We're excited to announce that our Noonan Spectrum Disorders/Rasopathies panel now has additional genes and a new lower price.

Opening Doors to Diagnosis: Chromosomal Microarray

Published on

We are pleased to announce new reduced pricing for our Chromosomal Microarray (CMA). CMA is often used as a first-tier test for clinical diagnosis of patients with idiopathic intellectual disability, developmental delay, autism spectrum disorders and/or multiple congenital anomalies (Miller, D.T. et al. 2010).

President's Corner - Quantitative Interpretation of Sequence Variants, Part 2  

Published on

In my previous President’s corner, I outlined the rationale for quantitative interpretation of sequence variants and presented our quantitative definitions of the five interpretation categories (Pathogenic, Likely Pathogenic, Uncertain, Likely Benign and Benign). In this Issue, I discuss in more detail two quantitative approaches with results and with limitations and pitfalls. 

Marshfield Based PreventionGenetics Earns Accreditation For Global Testing 

Published on

Marshfield, WI - PreventionGenetics, LLC, in Marshfield, Wisconsin achieved ISO 15189:2012 accreditation through the American Association for Laboratory Accreditation (A2LA). 

PreventionGenetics is one of few US based clinical genetic testing laboratories which have acquired the international quality assurance standard, making the company a provider of choice for international companies seeking NextGen panels, single gene tests, and deletion/duplication testing via high density gene-centric aCGH. 

Diagnosis Through the Power of Many: PGxome Now Available

Published on

We are excited to announce the launch of PGxome, PreventionGenetics' whole exome sequencing test!